Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shailender Bhatia

Showing results (71-80 of 123) with videos related to

Pageof 13
Sort By:
Journal of the American Academy of Dermatology|October 1, 2023
Increased risk of recurrence and disease-specific death following delayed postoperative radiation for Merkel cell carcinomaNora A Alexander, Stephanie K Schaub, Peter H Goff, et al.
Journal for Immunotherapy of Cancer|August 12, 2025
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 16, 2022
Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot studyArthur Sillah, Ulrike Peters, Nathaniel F Watson, et al.
The British Journal of Dermatology|July 27, 2025
Merkel Cell Carcinoma in Solid Organ Transplant Recipients: Prognosis and Response to ImmunotherapyTomoko Akaike, Peter Y Ch'en, Daniel S Hippe, et al.
The Journal of Experimental Medicine|June 1, 2016
Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patientAude G Chapuis, Sylvia M Lee, John A Thompson, et al.
Cancer Medicine|April 25, 2015
Single-fraction radiation therapy in patients with metastatic Merkel cell carcinomaJayasri G Iyer, Upendra Parvathaneni, Ted Gooley, et al.
Journal for Immunotherapy of Cancer|January 20, 2018
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trialHoward L Kaufman, Jeffery S Russell, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II StudyShailender Bhatia, Suzanne L Topalian, William Sharfman, et al.
Cancer Immunology, Immunotherapy : CII|September 21, 2023
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinomaLisa May Ling Tachiki, Daniel S Hippe, Karly Williams Silva, et al.
Cancer Immunology, Immunotherapy : CII|November 18, 2023
Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinomaLisa May Ling Tachiki, Daniel S Hippe, Karly Williams Silva, et al.
Pageof 13

Showing results (71-80 of 123) with videos related to

Sort By:
Pageof 13
Journal of the American Academy of Dermatology|October 1, 2023
Increased risk of recurrence and disease-specific death following delayed postoperative radiation for Merkel cell carcinomaNora A Alexander, Stephanie K Schaub, Peter H Goff, et al.
Journal for Immunotherapy of Cancer|August 12, 2025
Phase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201)Giovanni Grignani, Piotr Rutkowski, Céleste Lebbé, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|January 16, 2022
Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: a pilot studyArthur Sillah, Ulrike Peters, Nathaniel F Watson, et al.
The British Journal of Dermatology|July 27, 2025
Merkel Cell Carcinoma in Solid Organ Transplant Recipients: Prognosis and Response to ImmunotherapyTomoko Akaike, Peter Y Ch'en, Daniel S Hippe, et al.
The Journal of Experimental Medicine|June 1, 2016
Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patientAude G Chapuis, Sylvia M Lee, John A Thompson, et al.
Cancer Medicine|April 25, 2015
Single-fraction radiation therapy in patients with metastatic Merkel cell carcinomaJayasri G Iyer, Upendra Parvathaneni, Ted Gooley, et al.
Journal for Immunotherapy of Cancer|January 20, 2018
Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trialHoward L Kaufman, Jeffery S Russell, Omid Hamid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 31, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II StudyShailender Bhatia, Suzanne L Topalian, William Sharfman, et al.
Cancer Immunology, Immunotherapy : CII|September 21, 2023
Extended duration of treatment using reduced-frequency dosing of anti-PD-1 therapy in patients with advanced melanoma and Merkel cell carcinomaLisa May Ling Tachiki, Daniel S Hippe, Karly Williams Silva, et al.
Cancer Immunology, Immunotherapy : CII|November 18, 2023
Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinomaLisa May Ling Tachiki, Daniel S Hippe, Karly Williams Silva, et al.
Pageof 13